We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-4.17%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.49B
AUM Growth
-$101M
Cap. Flow
+$10.3M
Cap. Flow %
0.69%
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
56
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$24.6M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.2M
3
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$11.2M
4
BMY icon
Bristol-Myers Squibb
BMY
+$10.9M
5
MRK icon
Merck
MRK
+$9.97M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$35.8M
2
HCA icon
HCA Healthcare
HCA
+$32.5M
3
MCK icon
McKesson
MCK
+$13.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.83M
5
GI
EndoChoice Holdings, Inc.
GI
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 81.35%
2 Financials 4.56%
3 Industrials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRC
101
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$2.67M 0.18%
47,500
-72,500
-60% -$4.11M
EXEL icon
102
Exelixis
EXEL
$13.4B
$2.61M 0.17%
175,000
+50,000
+40% +$721K
MDGL icon
103
Madrigal Pharmaceuticals
MDGL
$11.8B
$2.61M 0.17%
174,891
+111,891
+178% +$1.8M
DBVT
104
DBV Technologies
DBVT
$847M
$2.56M 0.17%
7,300
– –
SCYX icon
105
SCYNEXIS
SCYX
$52M
$2.42M 0.16%
9,500
+1,562
+20% +$457K
RIGL icon
106
Rigel Pharmaceuticals
RIGL
$750M
$2.38M 0.16%
100,000
-81,000
-45% -$2.32M
EGLT
107
DELISTED
Egalet Corporation
EGLT
$2.29M 0.15%
300,000
– –
SYRE icon
108
Spyre Therapeutics
SYRE
$9.25B
$2.28M 0.15%
20,964
– –
MCRB icon
109
Seres Therapeutics
MCRB
$48.4M
$2.18M 0.15%
11,000
– –
ZBH icon
110
Zimmer Biomet
ZBH
$18.4B
$2.18M 0.15%
+21,733
New +$2.33M
HQY icon
111
HealthEquity
HQY
$8.75B
$2.03M 0.14%
+50,000
New +$1.93M
GNCA
112
DELISTED
Genocea Biosciences, Inc.
GNCA
$1.98M 0.13%
60,000
– –
BLUE
113
DELISTED
bluebird bio
BLUE
$1.76M 0.12%
2,200
+656
+42% +$521K
NVCR icon
114
NovoCure
NVCR
$1.91B
$1.68M 0.11%
214,316
– –
GBT
115
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.39M 0.09%
96,500
-1,500
-2% -$26.4K
TNDM icon
116
Tandem Diabetes Care
TNDM
$1.56B
$1.28M 0.09%
59,500
– –
DMTX
117
DELISTED
Dimension Therapeutics, Inc
DMTX
$1.18M 0.08%
271,370
– –
MYOV
118
DELISTED
Myovant Sciences Ltd.
MYOV
$1.11M 0.07%
+89,600
New +$1.04M
ALPN
119
DELISTED
Alpine Immune Sciences Inc
ALPN
$1.09M 0.07%
122,250
– –
BHC icon
120
Bausch Health
BHC
$2.34B
$1.04M 0.07%
71,400
+2,800
+4% +$51.4K
NVAX icon
121
Novavax
NVAX
$1.31B
$1.03M 0.07%
41,000
-1,625
-4% -$47.4K
ATYR
122
aTyr Pharma
ATYR
$50.1M
$1.02M 0.07%
33,929
+2,965
+10% +$122K
CHMA
123
DELISTED
Chiasma, Inc. Common Stock
CHMA
$960K 0.06%
492,500
– –
PRGO icon
124
Perrigo
PRGO
$1.78B
$774K 0.05%
9,300
-28,600
-75% -$2.48M
DVAX
125
DELISTED
Dynavax Technologies
DVAX
$652K 0.04%
165,000
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Rock Springs Capital Management held 143 positions worth $1.49B, down 6.3% from $1.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2016 filing shows 5 new, 56 increased, 18 reduced and 10 closed positions. Its largest new stake was UnitedHealth: 165,000 shares worth $26.4M. The largest sale was Pfizer, an estimated $35.8M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Financials and Industrials.

  • Rock Springs Capital Management's largest Q4 2016 buy was UnitedHealth: 165,000 shares worth $26.4M.
  • Rock Springs Capital Management added most to Alexion Pharmaceuticals in Q4 2016, an estimated $24.2M increase.
  • Rock Springs Capital Management's biggest Q4 2016 reduction was Gilead Sciences, cutting an estimated $5.02M.
  • Rock Springs Capital Management fully exited Pfizer in Q4 2016, selling an estimated $35.8M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $1.49B portfolio in Q4 2016.
  • Rock Springs Capital Management opened 5 new positions and closed 10 in Q4 2016.
  • Rock Springs Capital Management's portfolio value fell 6.3% quarter-over-quarter to $1.49B.

Based on Rock Springs Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.